Patents Assigned to Adagene Inc.
-
Patent number: 11952681Abstract: Provided herein are libraries containing synthetic polynucleotides that encode activatable binding polypeptides. Further provided herein are activatable binding polypeptides and polypeptide libraries containing such activatable binding polypeptides. Also provided herein are vectors, vector libraries, cells, kits, and methods of making and using activatable polypeptide libraries.Type: GrantFiled: February 2, 2019Date of Patent: April 9, 2024Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du
-
Patent number: 11859003Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: GrantFiled: August 21, 2018Date of Patent: January 2, 2024Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Guizhong Liu, Yan Li, Jun Chen, Xiaohong She, Peter Cheung
-
Publication number: 20230287597Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody light chain with specific hypervariable regions HVR-L1, HVR-L2, and HVR-L3. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody light chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: ApplicationFiled: January 11, 2023Publication date: September 14, 2023Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Yan LI, Fangyong DU
-
Patent number: 11692036Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: GrantFiled: February 2, 2019Date of Patent: July 4, 2023Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
-
Patent number: 11585014Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody light chain with specific hypervariable regions HVR-L1, HVR-L2, and HVR-L3. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody light chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: GrantFiled: August 21, 2017Date of Patent: February 21, 2023Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Yan Li, Fangyong Du
-
Patent number: 11578426Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: GrantFiled: August 21, 2017Date of Patent: February 14, 2023Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Yan Li, Fangyong Du
-
Patent number: 11485977Abstract: Methods and systems for autoinduction of gene expression, without the need to add exogenous inducers. A dual genetic element system, which includes a first, high copy number genetic element comprising a first gene of interest that is under the control of an inducible promoter, and a second, low copy number genetic element comprising a gene encoding a transcriptional factor which, upon expression, regulates transcription from the inducible promoter, wherein activation of transcription from the inducible promoter does not require addition of an exogenous inducer.Type: GrantFiled: December 19, 2014Date of Patent: November 1, 2022Assignee: ADAGENE, INC.Inventors: Fangyong Du, Peter Peizhi Luo
-
Publication number: 20220204637Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: ApplicationFiled: December 28, 2021Publication date: June 30, 2022Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Yan LI, Guizhong LIU, Jun CHEN, Xiaohong SHE, Peter CHEUNG
-
Patent number: 11359016Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: GrantFiled: February 1, 2019Date of Patent: June 14, 2022Assignee: ADAGENE INC.Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
-
Patent number: 11242395Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: GrantFiled: August 21, 2018Date of Patent: February 8, 2022Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung
-
Publication number: 20210206855Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: ApplicationFiled: February 2, 2019Publication date: July 8, 2021Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
-
Publication number: 20200377608Abstract: Provided herein are methods relating to the use of CD137 Ligand (CD137L) expression; methods relating to the use of CD137L expression as a biomarker; and methods for predicting, assessing, and/or aiding in assessment of responsiveness of a subject in need thereof to treatment with particular anti-cancer therapies (e.g., an anti-CD137 antibody, a checkpoint blockade immunotherapy).Type: ApplicationFiled: November 30, 2018Publication date: December 3, 2020Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Guizhong LIU, Fangyong DU
-
Publication number: 20200369776Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: ApplicationFiled: August 21, 2018Publication date: November 26, 2020Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU, Yan LI, Jun CHEN, Xiaohong SHE, Peter CHEUNG
-
Publication number: 20200362019Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody light chain with specific hypervariable regions HVR-L1, HVR-L2, and HVR-L3. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody light chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: ApplicationFiled: August 21, 2017Publication date: November 19, 2020Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Yan LI, Fangyong DU
-
Publication number: 20200248336Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.Type: ApplicationFiled: August 21, 2017Publication date: August 6, 2020Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Yan LI, Fangyong DU
-
Publication number: 20190241662Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: ApplicationFiled: February 1, 2019Publication date: August 8, 2019Applicant: ADAGENE INC.Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
-
Publication number: 20190241886Abstract: Provided herein are libraries containing synthetic polynucleotides that encode activatable binding polypeptides. Further provided herein are activatable binding polypeptides and polypeptide libraries containing such activatable binding polypeptides. Also provided herein are vectors, vector libraries, cells, kits, and methods of making and using activatable polypeptide libraries.Type: ApplicationFiled: February 1, 2019Publication date: August 8, 2019Applicant: ADAGENE INC.Inventors: Fangyong Du, Peter Peizhi Luo
-
Publication number: 20190055314Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: ApplicationFiled: August 21, 2018Publication date: February 21, 2019Applicant: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung